Exosomal new crown vaccine announces preclinical data, all variants are "universal"

April 22, 2022 / eMedClub News / -- Codiak BioSciences (NASDAQ: CDAK), which focuses on the development of new exosome drugs, recently announced that it announced at the 2022 World Vaccine Conference in Washington, D.
C.
Preclinical data on an engineered exosome-based pan-beta coronavirus vaccine
.

The project aims to prevent all SARS-CoV-2 variants and possible future new strains of the beta-coronavirus family
.

This pan-beta coronavirus vaccine induces cross-neutralizing antibody protection against multiple coronavirus strains, as well as antigen-specific and comprehensive immune responses against structurally conserved regions of multiple coronavirus variants
.

Based on Codiak's exoVACC™ platform and core technology engEx™, the vaccine can simultaneously integrate multiple complex antigens, adjuvants (to achieve immune enhancement), cell-targeted ligands, and immune costimulatory molecules into a single exosome.
Actively target antigen-presenting cells (APCs) to drive and enhance the immune response of the human immune system
.

▲ Codiak’s exoVACC™ platform (Image credit: Codiak) T cell epitopes used in vaccine constructs were identified by Ragon Institute Principal Investigator Dr.
Gaurav Gaiha
.

These structural fragments of the virus are thought to be invariant, enabling vaccine candidates to generate CD8 T cell responses that may be protective against all betacoronaviruses and, in preclinical models of SARS-CoV-2, help Further enhance the overall immune response
.

In June 2020, Codiak and the Ragon Institute reached two strategic collaborations to jointly develop engineered exosome-based vaccines against coronavirus and human immunodeficiency virus (HIV) using the exoVACC platform, a modular vaccine system established by Codiak.

.

Preclinical data presented late last year showed that Codiak's SARS-CoV-2 vaccine candidate stimulates a comprehensive immune response, including antibody and T-cell-mediated immunity, medium- and mid-range immunity against multiple SARS-CoV-2 variants.
and antibody responses, and were able to induce non-antigen-specific T cell responses against structurally conserved regions of all known related coronavirus variants
.

Additional preclinical findings presented this time provide further support for the vaccine's potential, with key conclusions including: the vaccine demonstrated evidence of durable antibody responses in mouse models lasting at least eight months; Mucosal immune responses were induced in mice that were comparable to those of mRNA vaccines in humans, and lung-resident memory CD4 and CD8 T cells were induced when administered intranasally; with SARS-CoV1 and SARS-CoV Vaccination with exosomes of the RBD protein of -2 was able to generate cross-protective neutralizing antibodies; after challenge with the Delta variant, mice survived 100% and showed evidence of minimal infection in lung tissue
.

▲ Evaluation of the protective effect against the new crown (Image source: Codiak) Representative companies in the field of exosomes: Codiak Codiak bioscience is one of the most representative companies in the field of exosomes in the world, and was listed on Nasdaq in October 2020
.

The engEx™ platform is Codiak's proprietary exosome therapeutic "engine" for the design and manufacture of novel exosome product candidates designed to target multiple pathways throughout the body
.

Based on this platform, Codiak can engineer exosomes with precisely engineered properties and integrate various types of bioactive molecules and direct them to specific cell types and tissues
.

Based on this platform, Codiak has advanced three engineered exosome therapeutic candidates into clinical studies, including exoIL-12, exoSTING and exoASO-STAT6
.

▲ Codiak’s clinical-stage pipeline targets exoIL-12 for cutaneous T-cell lymphoma (CTCL), carries IL-12 on the surface of exosomes, delivers IL-12 into the tumor microenvironment (TME), and enhances the dose control of IL-12 while limiting its systemic exposure and associated toxicity; can be used to treat CTCL, melanoma, Merkel cell carcinoma, Kaposi's sarcoma, glioblastoma multiforme, and triple-negative breast cancer
.

exoSTING for solid tumors is Codiak’s second engineered exosome drug candidate designed to utilize exosomes to deliver STING (interferon gene stimulator) agonists to tumor-resident antigen-presenting cells (APCs) for localized Activates the innate immune response to achieve tumor killing
.

Recommended reading: Intratumoral administration of Codiak engineered exosomes has positive initial clinical data in Phase 1/2, with obvious anti-tumor effectYimai Meng’s exoASO-STAT6 for primary liver cancer is designed to selectively convert antisense Oligonucleotides (ASOs) delivered to M2 macrophages target and reduce the immunosuppressive transcription factor STAT6
.

exoASO-STAT6 was able to efficiently reprogram the anti-inflammatory, pro-reparative M2 phenotype to the pro-inflammatory, cytotoxic M1 phenotype, thereby promoting on-target antitumor activity
.

Recommended reading: Exosomes and oligonucleotides join forces to fight cancer! This innovative therapy is advancing to the clinicYimai Meng broke the news Conclusion Although the development of exosomes is still in the early stage, the technology related to exosomes has developed rapidly in the past few years, and more and more exosome-based therapies are in preclinical or Efficacy and potential in early clinical stages
.

Codiak has widely deployed innovative therapies in the fields of tumors and infectious diseases based on exosome delivery, which is another manifestation of exosomes as a revolutionary natural transport system and drug carrier
.

Recommended reading: Another exosome therapy has been approved for clinical use.
What are the other application fields of exosomes? References: 1.
https:// .
https://——List of recent popular activities——▼On April 22, the thermal stability evaluation of DSC technology in ADC drugs was reviewed▼On April 25, Quality Control Strategy for AAV Gene Therapy Products and Processes